Table 2.

Prevalence of receiving destructive/topical therapies and risk of developing SCC and BCC in parallel to destructive/ topical therapy during follow-up

	Total	Developed SCC (n = 189)		Developed BCC (n = 169)
	(n = 613)	N (%)	IRR (95% CI)a	N (%)	IRR (95% CI)b
Destructive treatment
No	307	39 (13)		46 (15)
Yes	306	150 (49)	2.1 [1.4–3.1]	123 (40)	1.1 [0.8–1.7]
Cryotherapy/diathermy
No	335	50 (15)		58 (17)
Yes	278	139 (50)	1.9 [1.3–2.7]	111 (40)	1.2 [0.9–1.7]
Topical treatment
No	492	116 (24)		109 (22)
Yes	121	73 (60)	1.7 [1.2–2.3]	60 (50)	1.2 [0.9–1.7]

SCC squamous cell carcinoma, BCC basal cell carcinoma, IRR incidence rate ratio, CI confidence interval

^aAdjusted for age, sex, type of transplant, skin color and history of skin cancers excised/treated (Nil, ≤ 5, 6–10 and > 10)

^bAdjusted for age, sex, type of transplant, education and history of skin cancers excised/treated (Nil, ≤ 5, 6–10 and > 10)